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Abstract
Background: The role of inflammation in mood disorders has received increased attention. There is substantial evidence 
that cytokine therapies, such as interferon alpha (IFN-alpha), can induce depressive symptoms. Indeed, proinflammatory 
cytokines change brain function in several ways, such as altering neurotransmitters, the glucocorticoid axis, and apoptotic 
mechanisms. This study aimed to evaluate the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort 
of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with 
cytokine-induced depression.
Methods: We recruited 344 Caucasian outpatients with chronic hepatitis C, initiating IFN-alpha and ribavirin therapy. All 
patients were euthymic at baseline according to DSM-IV-R criteria. Patients were assessed at baseline and 4, 12, 24, and 
48 weeks after treatment initiation using the Patient Health Questionnaire (PHQ), the Hospital Anxiety and Depression 
Scale (HADS), and the Temperament and Character Inventory (TCI). We genotyped several functional polymorphisms of 
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interleukin-28 (IL28B), indoleamine 2,3-dioxygenase (IDO-1), serotonin receptor-1A (HTR1A), catechol-O-methyl transferase 
(COMT), glucocorticoid receptors (GCR1 and GCR2), brain-derived neurotrophic factor (BDNF), and FK506 binding protein 5 
(FKBP5) genes. A survival analysis was performed, and the Cox proportional hazards model was used for the multivariate 
analysis.
Results: The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48. The genotypic distributions were 
in Hardy-Weinberg equilibrium. Older age (p = 0.018, hazard ratio [HR] per 5 years = 1.21), presence of depression history 
(p = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (p = 0.005, HR = 1.13) increased the risk of IFN-
induced depression. So too did TCI personality traits, with high scores on fatigability (p = 0.0037, HR = 1.17), impulsiveness 
(p  =  0.0200 HR  =  1.14), disorderliness (p  =  0.0339, HR  =  1.11), and low scores on extravagance (p  =  0.0040, HR  =  0.85). An 
interaction between HTR1A and COMT genes was found. Patients carrying the G allele of HTR1A plus the Met substitution 
of the COMT polymorphism had a greater risk for depression during antiviral treatment (HR = 3.83) than patients with the 
CC (HTR1A) and Met allele (COMT) genotypes. Patients carrying the HTR1A CC genotype and the COMT Val/Val genotype 
(HR  =  3.25) had a higher risk of depression than patients with the G allele (HTR1A) and the Val/Val genotype. Moreover, 
functional variants of the GCR1 (GG genotype: p = 0.0436, HR = 1.88) and BDNF genes (Val/Val genotype: p = 0.0453, HR = 0.55) 
were associated with depression.
Conclusions: The results of the study support the theory that IFN-induced depression is associated with a complex 
pathophysiological background, including serotonergic and dopaminergic neurotransmission as well as glucocorticoid and 
neurotrophic factors. These findings may help to improve the management of patients on antiviral treatment and broaden 
our understanding of the pathogenesis of mood disorders.
Keywords: 5HT1A, COMT, depression, GCR1, genetic, hepatitis C, inflammation pathways, personality traits, risk factors
Background
The role of inflammation in mood disorders has received 
increased attention (Dowlati et  al., 2010; Moylan et  al., 2013; 
Zhang et al., 2015). Indeed, depression is prevalent in patients 
with inflammatory medical conditions, including cardiovascular 
diseases, rheumatoid arthritis, autoimmune disorders, obesity, 
or chronic hepatitis C (CHC; Evans et al., 2005). Moreover, there is 
substantial evidence that cytokine therapies can induce depres-
sive symptoms (Martín-Santos et al., 2008; Raison et al., 2009; 
Huckans et  al., 2015). Not only is antiviral treatment for CHC 
associated with a high incidence of fatigue, insomnia, irritability 
and low mood, but full major depressive episodes (MDE) are also 
observed in around 25% of patients (Udina et al., 2012).
Given that some patients are more likely to present depres-
sion during treatment with cytokines such as interferon alpha 
(IFN-alpha), research has focused on identifying social, clinical, 
and biological factors that may lead to neuropsychiatric side 
effects (Smith et al., 2012). Previous studies and meta-analyses 
have shown several risk factors for IFN-induced depression, 
including clinical factors such as subthreshold depressive symp-
toms at baseline, a history of depression, and certain personal-
ity traits, as well as sociodemographic factors such as female 
gender and low educational level (Raison et al., 2005a; Castellvi 
et al., 2009; Udina et al., 2012; Martin-Santos et al., 2015).
Although the exact neurobiological basis of cytokine-induced 
depression is not known, there is evidence that administra-
tion of an exogenous cytokine such as IFN-alpha modulates 
the function of cytokines such as interleukin-6 (IL-6) or inter-
leukin-28 (IL-28; Fernández-Rodriguez et al., 2013). In turn, this 
may result in both the treatment-induced antiviral response 
(Jimenez-Sousa et al., 2013) and antiviral-induced neuropsychi-
atric side effects (Udina et  al., 2013). Cytokine-induced altera-
tions within the central nervous system (CNS) may depend on 
various mechanisms, including the passage of cytokines through 
leaky regions of the blood-brain barrier and activation of nerv-
ous pathways (Anisman, 2009). A  high concentration of pro-
inflammatory cytokines with activity in the CNS may modulate 
monoamine neurotransmission (Raison et  al., 2009), alter the 
glucocorticoid axis, and dysregulate apoptotic mechanisms (Cai 
et  al., 2005; Asnis and De La Garza, 2006; Raison et  al., 2010a), 
which are factors related with the onset of clinical depression 
(Anisman, 2009). Specifically, immunological mechanisms may 
modulate the function of indoleamine 2,3-dioxygenase (IDO-1; 
Kim et al., 2012), serotonin receptors (5HT1A; Cai et al., 2005; Le 
Francois et al., 2008), and catechol-O-methyl transferase (COMT; 
Tchivileva et al., 2009), and thereby alter serotonin and dopamine 
neurotransmission in certain brain regions involved with the 
pathogenesis of depression (Frisch et al., 1999). Equally, chronic 
activation of the immune system is known to cause increased 
plasma cortisol levels by desensitizing glucocorticoid recep-
tors (GCR1 and GCR2; Cai et al., 2005; Silverman and Sternberg, 
2012) that may be modulated by proteins such as FK506-binding 
protein 5 (FKBP5), which is a co-chaperone of the glucocorticoid 
receptors (Menke et  al., 2013; Höehne et  al., 2014). Lastly, high 
concentrations of cytokines in the CNS have been associated 
with dysregulation of brain apoptotic mechanisms, such as the 
brain-derived neurotrophic factor (BDNF), and with increases in 
the levels of several oxidative factors (Gibney et al., 2013).
In view of this evidence, the study of biological factors that may 
lead to IFN-induced neuropsychiatric symptoms is of potential 
interest, as it may help to improve the management of patients 
receiving antiviral treatment and illuminate the pathogenesis of 
depression. Thus, we aimed to investigate the association between 
IFN-induced depression and functional genetic variants in immu-
nological factors (IL28), monoamine neurotransmission (IDO, 
5HT1A, COMT), and the glucocorticoid axis (GCR1, GCR2, FKBP5), 
and neurotrophic factors (BDNF) in patients with CHC.
Methods
Selection of Patients
All consecutive Caucasian outpatients with CHC infection who 
were candidates for combination treatment with pegylated 
interferon-alpha (PegIFN alpha) and ribavirin (RBV) were 
recruited between 2005 and 2009 at the Liver Unit of a general 
teaching hospital (Parc de Salut Mar) in Barcelona. The exclusion 
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criteria for the study were as follows: unable to understand the 
Catalan or Spanish languages, the presence of concomitant liver 
disease, decompensated cirrhosis or hepatocarcinoma, cur-
rent drug or alcohol abuse, and any depressive episode within 
a 24-week period before starting treatment. The sample in this 
study partially overlapped with that described in a previous 
article (Udina et al., 2013). The institutional review board at our 
hospitals (Parc de Salut Mar and Hospital Clínic) approved the 
study protocol and all participants provided written informed 
consent, including consent for genetic study.
Study Design
This study used a prospective cohort design. All patients were 
interviewed at baseline using the Structured Clinical Interview 
for DSM-IV Axis I Disorders (SCID-I; First et al., 1995) to assess 
their current and past history of psychiatric disorders. At base-
line, all patients also completed the Patient Health Questionnaire 
(PHQ; Spitzer et al., 1999), the Hospital Anxiety and Depression 
Scale (HADS; Zigmond and Snaith, 1983), and the revised 
Temperament and Character Inventory (TCI-R; Cloninger and 
Svrakic, 1997).
Patients started treatment with PegIFN alpha-2a (180  μg 
subcutaneously, per week) and RBV (800–1200 mg orally, per 
day) for 24 or 48 weeks according to the Hepatitis C virus (HCV) 
genotype. After 4, 12, 24, and 48 weeks of treatment, patients 
again completed the HADS and the PHQ. If, at any point during 
the study, patients met the criteria for any depressive disorder 
according to the PHQ they were referred to a senior psychiatrist 
on the same day. After a full clinical assessment, the psychia-
trists confirmed or rejected the diagnosis of depression, and ini-
tiated psychopharmacological treatment if needed.
Clinical Assessment
The validated Spanish version of the PHQ is designed to screen 
depressive and other psychiatric disorders in primary care and 
other medical settings (Diez-Quevedo et al., 2001; Navines et al., 
2012). The items on the PHQ correspond to the symptom crite-
ria for each disorder as outlined in the DSM-IV. The depression 
module (PHQ-9) has nine items with four response options: “Not 
at all,” “Several days,” “More than half the days,” and “Nearly 
every day.” We have also developed a categorical algorithm in 
which major depression is diagnosed if five or more of these 
criteria have been present at least “more than half the days” 
in the past 2 weeks, and if one of the symptoms is depressed 
mood or anhedonia; other depressive disorders are diagnosed 
if two, three, or four depressive symptoms have been present at 
least “more than half the days” in the past 2 weeks, and if one 
of the symptoms is depressed mood or anhedonia. The PHQ has 
good accuracy (95.2%) for detecting any depressive disorder in 
patients with CHC (Navines et al., 2012). Moreover, the diagno-
sis of any depressive disorder through the PHQ has convergent 
validity with the scores of the depression subscale of the HADS 
(Navines et al., 2012).
The HADS is a self-administered questionnaire with 14 items 
scored on a four-point Likert scale over depression and anxi-
ety subscales (HADS-D and HADS-A). It is particularly useful 
for patients with comorbid medical conditions, as it excludes 
somatic or vegetative symptoms from the depression subscale. 
In this study, the validated Spanish version of the HADS was 
used (Herrero et al., 2003).
The TCI-R (Cloninger and Svrakic, 1997) is a 240-item, five-
point Likert scale, self-report questionnaire that measures 
seven personality dimensions. The biopsychosocial model by 
Cloninger et  al. (1993) proposed that personality is formed by 
four temperament dimensions (harm avoidance, novelty seek-
ing, reward dependence, and persistence) and three character 
dimensions (self-directedness, cooperativeness, and self-tran-
scendence). Each dimension has three to five subscales measur-
ing specific personality traits. The validated Spanish version of 
the TCI-R questionnaire (Gutierrez-Zotes et al., 2004) was used 
in this study.
HCV RNA levels were measured by COBAS AMPLICOR HCV 
(Roche) at weeks 4, 12, and 24 and at week 48 in patients with 
genotype 1, and at week 24 after completion of antiviral treat-
ment to evaluate sustained virological response.
Genetic Variant Selection
We selected one variant in each of the following genes: inter-
leukin-28 (IL28B; rs8099917); indoleamine 2,3-dioxygenase 
(IDO-1; rs3824259); 5-hydroxytryptamine (serotonin) receptor 
1A (HTR1A; rs6295); COMT (rs4860); nuclear receptor subfamily 
3, group C, member 1 (glucocorticoid receptor; NR3C1; rs6196); 
nuclear receptor subfamily 3, group C, member 2 (NR3C2; 
rs5522); BDNF (rs6265); and FK506 binding protein 5 (FKBP5; 
rs1360780). To do so, we selected eight single nucleotide poly-
morphisms (SNPs) with a minor allele frequency higher than 
10% in Caucasian populations that had previously been reported 
in the literature to be involved in psychiatric disorders or to be 
potentially functional in a public dbSNP database (http://www.
ncbi.nlm.nih.gov/SNP/). Overall descriptions of each polymor-
phism are shown in Table 1.
SNP Genotyping
SNPs were genotyped using a custom VeraCode GoldenGate 
Genotyping Assay (Illumina) according to the manufacturer’s 
protocols (http://www.illumina.com). We used the Bead Studio 
software (Illumina) to process raw data, and genotypes were 
inferred via a genotyping cluster. For statistical analyses, we 
selected the SNPs with a minimum genotyping rate of 95% and 
in Hardy–Weinberg equilibrium (p > 0.05; see Table 1).
Statistical Analysis
To study possible risk factors for the incidence of any depres-
sive disorder, we used a survival analysis approach; a logistic 
model was inappropriate since the time under study was dif-
ferent between patients. Instead, the time from treatment start 
until the onset of the depression was chosen as the response 
variable of interest. Hence, right-censored data were given in the 
case of patients without depression during the study period, and 
the time to incidence was interval-censored between the last 
medical visit without depressive syndrome and the first after 
the onset, in all other cases. At a univariate level, the role of 
categorical variables was studied with the Fleming–Harrington 
test for interval-censored data based on a score vector distribu-
tion (Gómez et al., 2009), and the role of continuous variables 
by univariate Weibull regression models. All variables with a 
corresponding p-value below 0.25 were initially considered for 
the multivariate Weibull regression model, which is equivalent 
to the Cox proportional hazards model. The final model was 
obtained following the variable selection approach proposed 
by Hosmer and Lemeshow (2000). Possible interactions were 
considered between all variables of the resulting model. The 
cumulative incidence of depression at weeks 24 and 48 was 
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estimated using the Turnbull estimator for interval-censored 
data (Turnbull, 1976). All statistical analyses were carried out 
with the statistical software package R (The R Foundation for 
Statistical Computing), version 3.2.1; in particular, we used the 
contributed packages survival (https://cran.r-project.org/web/
packages/survival/index.html), FHtest (https://cran.r-project.
org/web/packages/FHtest/index.html), and Icens (http://www.
bioconductor.org/packages/release/bioc/html/Icens.html).
Results
Sample Characteristics
The clinical and sociodemographic characteristics of the 344 
patients included in the study are displayed in Table 2.
Incidence of IFN-Induced Depression
The cumulative incidence of depression was 0.35 at week 24 and 
0.46 at week 48 (see Figure 1). Some patients received treatment 
over 24 weeks and others over 48 weeks, depending on virus 
genotype and other medical criteria: the mean and median 
time under treatment were 37.3 and 47.8 weeks, respectively. 
The mean HADS-D score rate at the time of the first diagnosis of 
depression was 8.7 (standard deviation = 4.2). No suicidality was 
detected in the sample during the time of the study.
Predictive Variables of IFN-Induced Depression
Table 2 shows all the variables that were evaluated and the results 
of univariate analysis. All variables with a corresponding p-value 
below 0.25 were initially included in the multivariate analysis.
The multivariate model showed that older age (p  =  0.018, 
HR associated to a 5-year increase = 1.21), a history of depres-
sion (p = 0.0001, HR = 2.38), and subthreshold depressive symp-
toms at baseline (p  =  0.0050, HR  =  1.13) increased the risk of 
IFN-alpha–induced depression. Concerning personality traits 
measured with the TCI-R, high scores on fatigability (p = 0.0037, 
HR associated to a 5-point increase  =  1.17), impulsiveness 
(p  =  0.0200, HR associated to a 5-point increase  =  1.14), disor-
derliness (p = 0.0339, HR associated to a 5-point increase = 1.11), 
and low scores on extravagance (p = 0.0040, HR associated to a 
5-point increase = 0.85) were risk factors for depression during 
antiviral treatment. A history of anxiety (p = 0.0955) and human 
immunodeficiency virus (HIV) infection (p  =  0.0781) showed a 
trend toward an association with depression (see Table 3).
With regard to genetic polymorphisms, the following 
were risk factors for depression during antiviral treatment: 
being homozygous for the A allele of the GCR1 polymorphism 
(p = 0.029, HR = 1.88) and the genotype GG of the BDNF polymor-
phism (p = 0.0453 HR = 1.53; see Table 3).
Interaction Between Variables
In addition, we found an interaction between the HTR1A and 
COMT genes: patients carrying the HTR1A G allele had a higher 
risk of depression than those with the CC genotype if they also 
carried the A allele (Met/Met or Val/Met) of the COMT polymor-
phism (HR = 3.83). The G allele was not a risk factor in patients 
with the GG genotype (Met/Met) of COMT (HR  =  0.45). Among 
patients with the HTR1A CC genotype, those patients carrying the 
COMT GG genotype were at a higher risk of depression during 
antiviral treatment than patients carrying the A allele (HR = 3.25), 
whereas the GG allele was not a risk factor in patients with the 
HTR1AC G genotype (HR = 0.39; see Table 3 and Figure 2). No other 
interactions were found between any other variables studied.
Discussion
We evaluated the impact on mood of initiating IFN-alpha and riba-
virin treatment in a cohort of 344 euthymic patients with CHC. We 
found a higher incidence of depression in elderly patients, those 
with a history of depression, and those with depressive symptoms 
at baseline, as well as with certain personality traits. In addition, 
significant associations were found with functional variants of 
genes, such as GCR1 and BDNF, and with combinations of HTR1A 
and COMT genes. Notably, the incidence of depression was higher 
in patients carrying both the Met substitution in COMT and the G 
allele in HTR1A and in those carrying both the Val/Val substitution 
in COMT and the CC genotype HTR1A. To our knowledge, this is 
the first report of an association between a GCR1 gene polymor-
phism and IFN-alpha treatment-related depression.
The cumulative incidence of depression during antiviral treat-
ment was similar to previous reports (Robaeys et al., 2007; Castellvi 
et al., 2009). Some authors, however, have observed a lower inci-
dence of IFN-induced depression (Schäfer et al., 2007; Raison et al., 
2010b), probably due to the exclusion of patients with a history of 
depression or concomitant viral infections such as HIV.
According to our results, a previous history of depression 
and the presence of subthreshold depressive symptoms at 
baseline were both predictors of IFN-induced depression. A his-
tory of anxiety and HIV infection only showed a trend toward 
Table 1. Description of the Genetic Variants Included in the Study
dbSNP ID* Gene Chr. Position** Alleles Function/Location in gene Genotyping Rate (%) MAF HWE
rs6295 HTR1A 5 63294321 C/G 5’ upstream 99.1 0.47 0.33
rs4680 COMT 22 18331271 G/A Coding non-synonymous Val158Met 100.0 0.48 0.2
rs6196 NR3C1 5 142641683 A/G Coding synonymous 99.7 0.10 1.0
rs5522 NR3C2 4 149576925 A/G Coding non-synonymous Val180Ile 99.7 0.09 0.75
rs6265 BDNF 11 27636492 C/G Coding non-synonymous Val66Met 100 0.47 0.33
rs3824259 IDO 8 39888750 T/G 5’ upstream 100 0.48 0.33
rs1360780 FKBP5 6 35715549 C/T Intronic 100 0.29 0.29
rs8099917 IL28B 19 44435005 T/G 5’ upstream 99.7 0.21 0.62
*Based in dbSNP 135 (http://www.ncbi.nlm.nih.gov/projects/SNP)
**Mapped to Genome Build 36.3
BDNF = brain-derived neurotrophic factor; Chr = chromosome; COMT = Catechol-O-methyl transferase; FKBP5 = FK506 binding protein 5; HWE = Hardy-Weinberg 
equilibrium; HTR1A = 5-hydroxytryptamine (serotonin) receptor 1A; IDO = indoleamine 2,3-dioxygenase; IL28B = interleukin-28; MAF = minor allele frequency; 
NR3C1 = nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor); NR3C2 = nuclear receptor subfamily 3, group C, member 2.
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Table 2. Sample description and univariate analysis of variables
Whole sample
n = 344
Euthymic
n = 209
Depression
n = 135
Qualitative variables n (%) n (%) n (%) p-Value
Gender
 Female 113 (32.8) 69 (33) 44 (32.6) 0.962
 Male 231 (67.2) 140 (67) 91 (67.4)
Civil status
 Engaged/married 239 (69.5) 145 (69.4) 94 (69.6) 0.996
 Single 62 (18) 37 (17.7) 25 (18.5)
 Widow/divorced 43 (12.5) 27 (12.9) 16 (11.9)
Education
 Primary 151 (43.9) 80 (38.3) 71 (52.6) 0.005
 Medium 137 (39.8) 92 (44) 45 (33.3)
 Superior 56 (16.3) 37 (17.7) 19 (14.1)
Immigrant
 No 269 (78.2) 165 (78.9) 104 (77) 0.706
 Yes 75 (21.8) 44 (21.1) 31 (23)
Job
 Active 257 (75.4) 161 (77.8) 96 (71.6) 0.169
 Unemployed/retired 84 (24.6) 46 (22.2) 38 (28.4)
Viral Genotype
 1 194 (56.4) 122 (58.4) 72 (53.3) 0.410
 2 16 (4.7) 12 (5.7) 4 (3)
 3 98 (28.5) 57 (27.3) 41 (30.4)
 4 36 (10.5) 18 (8.6) 18 (13.3)
HIV infection
 No 275 (79.9) 179 (85.6) 96 (71.1) 0.004
 Yes 69 (20.1) 30 (14.4) 39 (28.9)
Methadone treatment
 No 330 (96.2) 199 (95.7) 131 (97) 0.396
 Yes 13 (3.8) 9 (4.3) 4 (3)
Depression History
 No 212 (62.7) 155 (76) 55 (42.5) 0.000
 Yes 126 (37.3) 49 (24) 77 (57.5)
Anxiety History
 No 248 (73.4) 163 (79.9) 85 (63.4) 0.001
 Yes 90 (26.6) 41 (20.1) 49 (36.6)
Cocaine abuse history
 No 252 (74.6) 158 (77.5) 94 (70.1) 0.206
 Yes 86 (25.4) 46 (22.5) 40 (29.9)
Alcohol abuse history
 No 273 (80.8) 171 (83.8) 102 (76.1) 0.060
 Yes 65 (19.2) 33 (16.2) 32 (23.9)
Opioid abuse history
 No 242 (71.6) 154 (75.5) 88 (65.7) 0.116
 Yes 96 (28.4) 50 (24.5) 46 (34.3)
General psychiatric history
 No 180 (52.8) 126 (61.2) 54 (40) 0.000
 Yes 161 (47.2) 80 (38.8) 81 (60)
Family psychiatric history
 No 219 (64.6) 134 (65) 85 (63.9) 0.797
 Yes 120 (35.4) 72 (35) 48 (36.1)
Antidepressants at baseline
 No 302 (87.8) 189 (90.4) 113 (83.7) 0.064
 Yes 42 (12.2) 20 (9.6) 22 (16.3)
Quantitative variables Mean (SD) Mean (SD) Mean (SD)
Age 44 (10.4) 43.6 (10.4) 44.8 (10.3) 0.219
HADS depression baseline 2.5 (2.8) 1.9 (2.2) 3.5 (3.2) 0.000
Body mass index 25.1 (4.5) 25.3 (4.2) 24.7 (4.9) 0.403
Nº previous IFN treatments 1.2 (0.5) 1.2 (0.6) 1.2 (0.5) 0.730
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association. These have consistently been reported as risk fac-
tors in previous clinical studies and meta-analyses (Raison 
et al., 2005b; Castellvi et al., 2009; Udina et al., 2012).
Our finding of an association between certain personality 
traits and IFN-induced depression was also interesting. Previous 
studies have reported that high harm-avoidance, low self-
direction, and high neuroticism may be related to IFN-induced 
depression (Lotrich et  al., 2007; Castellvi et  al., 2009). In our 
study, all traits associated with depression (fatigability, impul-
siveness, disorderliness, extravagance) were from two tempera-
mental dimensions of the TCI-R: harm avoidance and novelty 
seeking. Temperamental dimensions assess differences in auto-
matic emotional responses to stimuli, define personality style, 
and are influenced by different neurotransmitter systems. Harm 
avoidance refers to a tendency to shyness and anxiety, and has 
been associated with serotonergic function (Tuominen et  al., 
2013), while novelty seeking reflects reward system activity and 
has been related to mesolimbic and mesocortical dopaminergic 
projections (Buskila et al., 2004; Tournier et al., 2013). However, 
despite these overall trends, we found no interactions between 
these variables and the functional polymorphisms examined.
The current study also found an association between the 
HTR1A polymorphism and IFN-alpha induced depression. The 
results are in agreement with those reported by Kraus et  al. 
(2007), where patients carrying the G allele of the HTR1A gene 
were at a higher risk of depression during antiviral treatment. 
Moreover, the same polymorphism has previously been associ-
ated with panic disorder, neuroticism, depression, and reduced 
response to antidepressant treatment (Le Francois et al., 2008). 
We found that the G allele in HTR1A only predicted depression 
in patients also carrying the A  allele (Met substitution) in the 
COMT gene (n  =  141). Interestingly, a small group of patients 
(n = 33) carrying the GG genotype in the COMT polymorphism 
(Val/Val substitution) together with the CC genotype in the 
HTR1A polymorphism also showed a higher incidence of depres-
sion. Importantly, both patient subgroups had more than a 
three-fold higher risk of depression during interferon treatment 
than those without this combination. The risk for these patients 
Whole sample
n = 344
Euthymic
n = 209
Depression
n = 135
Quantitative variables Mean (SD) Mean (SD) Mean (SD)
HADS anxiety baseline 4.5 (3.3) 3.9 (3.1) 5.5 (3.4) 0.000
TCI-R Novelty Seeking 50.3 (9.9) 50.3 (9.7) 50.2 (10.3) 0.684
 Exploratory excitability 48.9 (10.4) 50.1 (10.2) 47 (10.4) 0.010
 Impulsiveness 50.7 (10.2) 49.8 (9.8) 52.3 (10.7) 0.035
 Extravagance 51.2 (10.2) 51.6 (10.2) 50.5 (10.1) 0.163
 Disorderliness 49.9 (10.5) 49.2 (9.7) 51.2 (11.6) 0.151
TCI-R Harm Avoidance 52.6 (10.4) 50.9 (10.3) 55.4 (9.9) 0.000
 Anticipatory worry 51 (9.9) 49.6 (10) 53.3 (9.3) 0.001
 Fear of uncertainty 50.9 (10.6) 50.4 (10.4) 51.7 (10.7) 0.213
 Shyness 51.8 (10.1) 51 (9.7) 53 (10.6) 0.071
 Fatigability 54.2 (11.4) 51.8 (10.7) 58 (11.4) 0.000
TCI-R Reward Dependence 48.8 (9.5) 48.9 (8.8) 48.5 (10.7) 0.846
 Sentimentality 47.9 (10.7) 47.7 (10) 48.2 (11.7) 0.570
 Openness to warm  
 communication
49 (13.7) 49 (12.6) 49 (15.2) 0.918
 Attachment 49.3 (9.9) 49.2 (9.8) 49.4 (10.3) 0.886
 Dependence 49.8 (10.6) 50.6 (10.4) 48.5 (10.8) 0.104
TCI-R Persistence 48.6 (10.9) 48.4 (10.5) 49 (11.5) 0.509
 Eagerness of effort 49.3 (11.1) 49.6 (10.8) 49 (11.5) 0.854
 Work hardened 47.7 (10.3) 47.7 (10.4) 47.7 (10.3) 0.954
 Ambitious 49.1 (12.1) 48.6 (11.4) 49.9 (13.1) 0.330
 Perfectionism 49 (10.6) 48.6 (10.6) 49.8 (10.7) 0.250
TCI-R Self-directedness 50.4 (10.5) 52.3 (10) 47.5 (10.7) 0.000
 Responsibility 50.1 (11.3) 51.9 (10.3) 47.3 (12.3) 0.000
 Purposefulness 49.3 (11.4) 50.6 (10.6) 47.2 (12.3) 0.007
 Resourcefulness 50 (10.9) 51.1 (9.9) 48.3 (12.1) 0.019
 Self-acceptance 50.3 (10.4) 51.5 (9.7) 48.4 (11.1) 0.014
 Enlightened second nature 51.2 (10.9) 52.4 (11) 49.4 (10.5) 0.027
TCI-R Cooperativeness 49.5 (9.8) 50.8 (10) 47.5 (9.1) 0.010
 Social acceptance 50 (9.8) 51.1 (9.7) 48.1 (9.7) 0.010
 Empathy 49.6 (9.6) 50.1 (9.3) 48.8 (9.9) 0.303
 Helpfulness 48.7 (9.7) 49.6 (9.5) 47.3 (9.9) 0.066
 Compassion 49.2 (10.3) 50.1 (9.9) 47.8 (10.8) 0.080
 Poor-hearted consciousness 50.6 (11.2) 51.5 (11) 49.3 (11.4) 0.080
TCI-R Self-Transcendence 51.3 (11) 50.7 (11) 52.2 (11.1) 0.218
 Self-forgetful 50.6 (11.1) 50 (10.9) 51.5 (11.3) 0.231
 Transpersonal identification 50.8 (10.9) 50.6 (10.6) 51.1 (11.4) 0.511
 Spiritual acceptance 51.8 (11) 51.1 (10.8) 52.8 (11.4) 0.264
HADS, Hospital Anxiety and Depression Scale; INF, interferon; SD, standard deviation; TCI-R, Temperament and Character Inventory, revised
Table 2. Continued
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was even higher than in patients with a history of depression 
(HR 2.35), which is the most replicated and strongest risk fac-
tor for developing IFN-induced depression (Castellvi et al., 2009; 
Fransen Van De Putte et al., 2009; Udina et al., 2012).
Overall, these results suggest that both serotonin and dopa-
mine pathways are important in the development of depres-
sion during antiviral treatment for CHC. On the one hand, the 
G allele of HTR1A may alter transcription in serotonergic and 
non-serotonergic neurons and confers a higher susceptibility 
to depression and suicide (Lemonde et  al., 2003). Specifically, 
the G allele up-regulates 5-HT1A autoreceptor expression, which 
reduces serotonergic function in the forebrain and may also 
alter dopaminergic neurotransmission (Vollenweider et al., 1999; 
Albert et al., 2011). Furthermore, 5-HT1A receptors modulate the 
activity of dopaminergic neurons in the ventral tegmental area 
and regulate mesocortical dopamine release (Diaz-Mataix et al., 
Table 3. Multivariate Analysis
Value Standard error CI (2.5- 97.5) p HR
Age 0.0652 0.0209 0.106 0.024 0.0018 1.21*
HIV infection -0.7146 0.4057 0.080 -1.510 0.0781 1.51
History of mood disorder -1.5142 0.3944 -2.287 -0.741 0.0001 2.38
History of anxiety disorder -0.6375 0.3824 -1.387 0.112 0.0955 1.44
HADS score at baseline -0.2195 0.0781 -0.373 -0.066 0.0050 1.13
TCI HA: Fatigability -0.0552 0.0190 -0.092 -0.018 0.0037 1.17**
TCI NS: Impulsiveness -0.0468 0.0201 -0.086 -0.007 0.0200 1.14**
TCI NS: Extravagance 0.0551 0.0192 0.018 0.093 0.0040 0.85**
TCI NS: Disorderliness 0.0374 0.0176 -0.072 -0.003 0.0339 1.11**
5HT1A: G -2.3443 0.5966 -3.514 -1.175 <0.0001 -
COMT: GG (Val/Val) -2.0613 0.9225 -3.869 -0.253 0.0254 -
GCR1: G 1.0495 0.5201 0.030 2.069 0.0436 0.55
BDNF: GG (Val/Val) -0.7460 0.3726 -1.476 -0.016 0.0453 1.53
5HT1A * COMT 3.7231 1.0943 1.578 5.868 0.0007
- Val/Val: G vs. CC 0.45
- Met: G vs. CC 3.83
- CC:Val/Val vs. Met 3.25
- G:Val/Val vs. Met 0.39
Variables included in the analysis and with p < 0.1.
*Hazard ratio associated to a 5 years’ increase
**Hazard ratios associated to a 5 points’ increase
BDNF, brain-derived neurotrophic factor; CI, confidence interval; COMT, catechol-O-methyl transferase; HA, harm avoidance; HADS, Hospital Anxiety and Depression 
Scale; HR, hazard ratio; NS, novelty seeking; TCI, Temperament and Character Inventory
Figure 1. Estimated cumulative incidence of depression during antiviral treatment. Shaded areas indicate that the estimation of the cumulative incidence is not 
defined in the corresponding intervals, but only known to increase monotonically.
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2005). Capuron et al. (2012) also reported alterations in dopamin-
ergic neurons after IFN-alpha administration that might be asso-
ciated with anhedonia, fatigue, and other behavioral changes. 
On the other hand, dopamine plays a critical role in prefrontal 
cortex function in an inverted U-shaped manner, with both too 
much and too little dopamine being associated with a higher risk 
of depression (Meyer-Lindenberg et al., 2005; Honea et al., 2009). 
Such a phenomenon might explain the interaction between the 
COMT and HTR1A polymorphisms. The A allele (Met/Met or Val/
Met) in the COMT polymorphism is related to lower activity of 
the enzyme, and therefore probably to a higher concentration of 
dopamine in the prefrontal cortex (Chen et al., 2004). Moreover, 
the G allele of the HTR1A polymorphism may be associated with 
an up-regulation of 5HT1A receptor expression in the prefrontal 
cortex and a further release of dopamine. Therefore, patients 
carrying both alleles (COMT A and HTR1A G) may develop abnor-
mally high concentrations of dopamine in the prefrontal cortex, 
leading to a higher risk of IFN-induced depression. Alternatively, 
patients who simultaneously carry the GG genotype (Val/Val) in 
the COMT gene and the CC genotype in the HTR1A polymor-
phism may have abnormally low concentrations of dopamine 
that also result in a higher risk for depression. This theory is 
biologically plausible because patients with the other genotypes 
would have intermediate levels of dopamine and would there-
fore be at a lower risk of developing depression.
A novel association between GCR1 and antiviral-induced 
depression is worthy of note. Genetic variants of the GCR1 
gene have been associated with changes in corticosteroid 
resistance (Krupoves et  al., 2011), major depressive disorders 
(Szczepankiewicz et  al., 2011; Galecka et  al., 2013), and a pre-
dominance of depression in the course of bipolar disorder 
(Szczepankiewicz et al., 2011). This observation may be related to 
the cytokine-induced activation of the hypothalamic-pituitary-
adrenal axis, a physiological condition often related to depres-
sion (Vreeburg et al., 2009; Lok et al., 2012). Specifically, chronic 
administration of IFN-alpha is associated with a desensitiza-
tion of the hypothalamic-pituitary-adrenal axis, leading to a 
reduced negative feedback regulation and increased plasma cor-
tisol levels (Capuron et al., 2003; Cai et al., 2005; Silverman and 
Sternberg, 2012). Hence, a reduction in glucocorticoid receptor 
mRNA levels has been reported in patients with major depres-
sion (Webster et al., 2002; Perlman et al., 2004). Interestingly, IFN-
alpha markedly down-regulated HTR1A and GCR1 receptors in 
cell lines in vitro, an effect that was attenuated by the adminis-
tration of antidepressants (Cai et al., 2005). In this line, clinical 
studies showed that prophylactic administration of antidepres-
sants reduces the incidence of IFN-induced depression (Udina 
et al., 2014).
Lastly, we found an association between the BDNF polymor-
phism and depression during antiviral treatment. It is possible 
that activation of cytokines and inflammatory mediators in the 
brain could produce excitotoxicity and alterations in neuro-
trophic factors. Indeed, cytokines may stimulate the release of 
glutamate from glial cells and alter glutamate reuptake through 
glutamate transporters (Muller and Schwarz, 2007). The subse-
quent excessive activation of N-methyl-D-aspartate receptors 
by glutamate could then cause oxidative stress by producing 
reactive species of oxygen and nitrogen, thereby altering the 
expression of trophic factors such as BDNF (Muller and Schwarz, 
2007; Capuron and Miller, 2011). According to our results, the Val 
genotype of BDNF was associated with IFN-induced depression. 
In addition, this genotype was also associated with higher neu-
rotic scores and with anxiety- and depression-related personal-
ity traits, suggesting a relationship with depression (Sen et al., 
2003; Lang et al., 2005). Conversely, some studies have reported 
an association between the Met genotype and increased serum 
concentrations of BDNF (Lang et al., 2009) and with a risk fac-
tor for anxiety disorders, major depression (Jiang et  al., 2005), 
and even INF-induced depression (Lotrich et al., 2012). Gratacos 
et  al. (2007) reported that the Met  allele increases the risk of 
Figure 2. Estimated cumulative incidence of depression according to genotypes of HTR1A and COMT genes. Shaded areas indicate that the estimation of the cumula-
tive incidence is not defined in the corresponding intervals, but only known to increase monotonically.
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eating disorders and schizophrenia, while reducing the risk of 
substance-related disorders. Castren et  al. (2007) showed that 
increased BDNF concentrations in the hippocampus mimic 
the effects of antidepressants on behavior, but that injection 
of BDNF into the mesolimbic dopamine pathway produces an 
opposing response. As described in previous studies and meta-
analyses, the association between the BDNF Val66Met polymor-
phism and different psychiatric conditions is complex (Groves, 
2007; Verhagen et al., 2010). It is likely that neurotrophic factors 
themselves do not control mood, but that they may be crucial to 
the modulation of neural networks involved in the pathogenesis 
of depression, including serotonergic or dopaminergic pathways 
(Castren et al., 2007; Groves, 2007).
This study has some strengths and limitations. We con-
trolled for potential confounding variables at baseline, such as 
antidepressant use, a history of depression, and other relevant 
sociodemographic variables, and did not find an interaction 
between these variables and the polymorphisms examined. 
Although we did not control for antidepressant therapy being 
initiated during antiviral treatment, we doubt that this would 
influence our conclusions because therapy was only initiated 
after the clinical diagnosis of depression.
Sample size and the all-Caucasian population are also limi-
tations. To our knowledge, only two genetic studies evaluating 
patients with CHC under antiviral treatment have had larger 
samples; however, neither study used a standardized clinician-
administered assessment to establish the diagnosis of depres-
sion (Pierucci-Lagha et  al., 2010; Smith et  al., 2011), which we 
believe is a strength of our study. Nevertheless, it should be noted 
that antiviral treatment can induce two overlapping syndromes: 
a specific psychiatric syndrome of mood alterations, cognitive 
complaints, and anxiety, and a non-specific syndrome of neu-
rovegetative symptoms (Raison et al., 2005a). In this study, we 
only assessed patients using the HADS scale, which specifically 
excludes neurovegetative symptoms and avoids overlapping 
with other depression symptoms; this may be somewhat coun-
terbalanced by the fact that the mean HADS-D score was 8.7 at 
the onset of depression, suggesting the presence of a depres-
sive episode with high sensitivity and specificity (Olsson et al., 
2005). Another limitation of the study is that specific neuropsy-
chiatric symptoms of depression were not evaluated, which may 
be important. For example, insomnia has been associated with 
increased cytokine concentrations and with a polymorphism in 
the serotonin transporter gene (Lotrich et al., 2012).
Lastly, we did not find an association between the IDO, IL28, 
FKBP5, and GCR2 genetic variants. However, these results should 
be interpreted with care due to the small number of polymor-
phisms evaluated. For example, a previous study showed an 
association between another IDO gene variant (rs9657182) and 
IFN-induced depression, suggesting that IDO may have an 
important role in cytokine-induced behavioral changes (Smith 
et al., 2011).
In conclusion, this study supports the notion that IFN-
induced depression is a complex pathophysiological process 
in which specific factors interact with physiological changes 
that are associated with depressive symptoms. Consistent 
with previous reports, the serotonin pathway was important 
in the development of depression. However, factors such as the 
integrity of dopamine neurotransmission, vulnerability to glu-
cocorticoid resistance, and neurotrophin function may also be 
crucial.
Moreover, the results of the study should help to optimize 
the managment of patients with CHC, detecting those at high 
risk to present IFN-induced depression. In fact, recent guidelines 
recommend multidisciplinary monitoring for psychiatric symp-
toms during antiviral treatment for CHC in all cases (Schaefer, 
2012; Carrion et al., 2013). However, those in high risk to present 
depression may well benefit from certain interventions such 
as prophilactical treatment with antidepressants (Udina et al., 
2014). Although interferon-free regimens with direct-acting 
antivirals are recent options, currently interferon-alpha is still 
widely used in CHC in most countries (Ermis and Senocak Tasci, 
2015).
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